End-of-day quote
Nasdaq
06:00:00 2024-05-27 pm EDT
|
5-day change
|
1st Jan Change
|
11.9
USD
|
+0.42%
|
|
+0.42%
|
+5.97%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
153.1
|
345.7
|
443.5
|
-
|
-
|
Enterprise Value (EV)
1 |
153.1
|
254
|
363.5
|
418.4
|
450.2
|
P/E ratio
|
-0.72
x
|
-3.18
x
|
-6.29
x
|
-5.84
x
|
-5.67
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
391
x
|
475
x
|
45.8
x
|
13.2
x
|
EV / Revenue
|
-
|
288
x
|
389
x
|
43.2
x
|
13.4
x
|
EV / EBITDA
|
-
|
-3.16
x
|
-6.6
x
|
-11.1
x
|
59.3
x
|
EV / FCF
|
-
|
-4.68
x
|
-7.56
x
|
-8.57
x
|
-4.91
x
|
FCF Yield
|
-
|
-21.4%
|
-13.2%
|
-11.7%
|
-20.4%
|
Price to Book
|
-
|
3.69
x
|
3.46
x
|
4.84
x
|
4.52
x
|
Nbr of stocks (in thousands)
|
16,399
|
36,598
|
41,740
|
-
|
-
|
Reference price
2 |
9.336
|
9.445
|
10.63
|
10.63
|
10.63
|
Announcement Date
|
3/28/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.883
|
0.934
|
9.686
|
33.71
|
EBITDA
1 |
-
|
-80.43
|
-55.06
|
-37.74
|
7.594
|
EBIT
1 |
-
|
-80.71
|
-64.97
|
-66.5
|
-47.99
|
Operating Margin
|
-
|
-9,140.88%
|
-6,956.9%
|
-686.58%
|
-142.39%
|
Earnings before Tax (EBT)
1 |
-
|
-88.7
|
-65.69
|
-72.31
|
-70.38
|
Net income
1 |
-38.7
|
-88.8
|
-65.46
|
-74.54
|
-81.17
|
Net margin
|
-
|
-10,056.85%
|
-7,008.92%
|
-769.61%
|
-240.84%
|
EPS
2 |
-12.94
|
-2.970
|
-1.690
|
-1.821
|
-1.876
|
Free Cash Flow
1 |
-
|
-54.26
|
-48.1
|
-48.8
|
-91.7
|
FCF margin
|
-
|
-6,144.85%
|
-5,150.11%
|
-503.83%
|
-272.06%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.25
|
-
|
0.219
|
0.185
|
0.222
|
0.2603
|
0.2541
|
0.2215
|
-
|
-
|
EBITDA
|
-
|
-
|
-12.89
|
-12.11
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-10.74
|
-
|
-12.96
|
-12.18
|
-15.33
|
-15.78
|
-16.36
|
-17.54
|
-
|
-
|
Operating Margin
|
-4,298%
|
-
|
-5,917.35%
|
-6,585.95%
|
-6,904.5%
|
-6,060.03%
|
-6,436.35%
|
-7,916.71%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-12.76
|
-
|
-17.53
|
-12.51
|
-16.06
|
-15.88
|
-16.48
|
-17.13
|
-
|
-
|
Net income
1 |
-12.88
|
-
|
-17.41
|
-12.5
|
-16.09
|
-15.77
|
-16.33
|
-17.37
|
-
|
-
|
Net margin
|
-5,150.8%
|
-
|
-7,951.14%
|
-6,756.22%
|
-7,249.1%
|
-6,056.02%
|
-6,425.76%
|
-7,838.44%
|
-
|
-
|
EPS
2 |
-0.3800
|
-2.530
|
-0.4800
|
-0.3400
|
-0.4400
|
-0.4125
|
-0.4208
|
-0.4408
|
-0.3700
|
-0.3700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/29/23
|
8/29/23
|
11/15/23
|
3/18/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
6.69
|
Net Cash position
1 |
-
|
91.7
|
80
|
25.1
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
0.8805
x
|
Free Cash Flow
1 |
-
|
-54.3
|
-48.1
|
-48.8
|
-91.7
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-80.6%
|
-
|
6.86%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
2.560
|
3.070
|
2.190
|
2.350
|
Cash Flow per Share
2 |
-
|
-1.800
|
-1.990
|
-2.470
|
-
|
Capex
1 |
-
|
0.05
|
0.4
|
0.4
|
0.4
|
Capex / Sales
|
-
|
5.44%
|
42.83%
|
4.13%
|
1.19%
|
Announcement Date
|
3/28/23
|
3/18/24
|
-
|
-
|
-
|
Last Close Price
10.63
CHF Average target price
25.75
CHF Spread / Average Target +142.37% Consensus |
1st Jan change
|
Capi.
|
---|
| +5.97% | 491M | | +43.36% | 54.64B | | -5.31% | 39.92B | | +37.52% | 38.82B | | +14.75% | 26.86B | | -12.56% | 26.22B | | -22.45% | 18.78B | | +0.04% | 12.16B | | +25.12% | 12.21B | | +26.04% | 11.94B |
Other Biotechnology & Medical Research
|